BR112014008804A2 - suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos - Google Patents

suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos

Info

Publication number
BR112014008804A2
BR112014008804A2 BR112014008804A BR112014008804A BR112014008804A2 BR 112014008804 A2 BR112014008804 A2 BR 112014008804A2 BR 112014008804 A BR112014008804 A BR 112014008804A BR 112014008804 A BR112014008804 A BR 112014008804A BR 112014008804 A2 BR112014008804 A2 BR 112014008804A2
Authority
BR
Brazil
Prior art keywords
methods
specific
cd40l
carriers
relates
Prior art date
Application number
BR112014008804A
Other languages
English (en)
Inventor
Coyle Anthony
Kenneth Spencer David
Grinberg Luba
Baca Manuel
Herbst Ronald
Novarra Shabazz
Drabic Stacey
Thisted Thomas
Oganesyan Vaheh
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112014008804A2 publication Critical patent/BR112014008804A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

resumo patente de invenção: "suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos". a presente invenção refere-se a suportes baseados no domínio fniii de tenascina-3 que se ligam especificamente a cd40l. a invenção proporciona ainda variantes manipuladas com elevada afinidade para o alvo. a presente invenção também está relacionada com suportes manipulados como agentes profilácticos, de diagnóstico ou terapêuticos, em particular para fins terapêuticos contra les e outras doenças e condições autoimunes. 2/216
BR112014008804A 2011-10-11 2012-10-10 suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos BR112014008804A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161546028P 2011-10-11 2011-10-11
PCT/US2012/059477 WO2013055745A2 (en) 2011-10-11 2012-10-10 Cd40l-specific tn3-derived scaffolds and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112014008804A2 true BR112014008804A2 (pt) 2017-06-13

Family

ID=48082729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008804A BR112014008804A2 (pt) 2011-10-11 2012-10-10 suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos

Country Status (22)

Country Link
US (4) US10000553B2 (pt)
EP (2) EP2771022B1 (pt)
JP (4) JP6140712B2 (pt)
KR (3) KR20220116585A (pt)
CN (3) CN108948196B (pt)
AU (1) AU2012323316B2 (pt)
BR (1) BR112014008804A2 (pt)
CA (1) CA2851667A1 (pt)
CY (1) CY1123690T1 (pt)
DK (1) DK2771022T3 (pt)
ES (1) ES2819075T3 (pt)
HK (1) HK1201463A1 (pt)
HR (1) HRP20201513T1 (pt)
HU (1) HUE051439T2 (pt)
LT (1) LT2771022T (pt)
MX (2) MX367013B (pt)
PT (1) PT2771022T (pt)
RS (1) RS60828B1 (pt)
RU (2) RU2019133467A (pt)
SG (2) SG10201707813YA (pt)
SI (1) SI2771022T1 (pt)
WO (1) WO2013055745A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047164T2 (hu) * 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
HUE051439T2 (hu) * 2011-10-11 2021-03-01 Viela Bio Inc CD40L-re specifikus, TN3-eredetû állványok és alkalmazásuk
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9938356B2 (en) 2014-11-10 2018-04-10 Medimmune Limited Binding molecules specific for CD73 and uses thereof
BR112017019401A2 (pt) 2015-03-12 2018-05-02 Medimmune, Llc método de purificação de proteínas de fusão de albumina
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
US11958913B2 (en) * 2017-01-09 2024-04-16 Biomunex Pharmaceuticals Polypeptide linker for preparing multispecific antibodies
US11905313B2 (en) * 2017-11-28 2024-02-20 The United States of America, as represented by the Secretary, Department of Health and Human Services. Recombinant RSV G proteins and their use
AU2019347730A1 (en) * 2018-09-24 2021-03-25 Janssen Biotech, Inc. Method of providing safe administration of an anti-CD154 antibody
CA3114394A1 (en) * 2018-09-26 2020-04-02 Viela Bio, Inc. Cd40l antagonist and uses thereof
US20220090055A1 (en) * 2018-10-24 2022-03-24 Brandeis University Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family pgt128
EP3902824A4 (en) 2018-12-28 2023-01-04 Sparx Therapeutics Inc. FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES
CN111440253B (zh) * 2019-01-17 2021-08-27 中国科学院上海药物研究所 立方形环糊精骨架-rgd组合物及其制备方法
IL308488A (en) * 2021-05-21 2024-01-01 Viela Bio Inc CD40L antagonist and its uses in the treatment of lupus nephritis

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
DE69112207T2 (de) 1990-04-05 1996-03-28 Roberto Crea "walk-through"-mutagenese.
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH08501085A (ja) 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗腫瘍剤としてのサイトカインｉｐ−１０の利用
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1996008513A1 (en) 1994-09-16 1996-03-21 The Scripps Research Institute Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
AU731758B2 (en) 1998-07-08 2001-04-05 Mitsui Chemicals, Inc. Method for secretory production of human growth hormone
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU775997B2 (en) 1998-12-02 2004-08-19 Bristol-Myers Squibb Company DNA-protein fusions and uses thereof
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1196637T3 (da) 1999-07-27 2007-07-30 Adnexus Therapeutics Inc Peptidacceptor-ligeringsmetoder
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
ES2564161T3 (es) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6951725B2 (en) 2001-06-21 2005-10-04 Compound Therapeutics, Inc. In vitro protein interaction detection systems
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP2339017A3 (en) 2002-03-29 2011-10-12 Genencor International, Inc. Enhanced protein expression in bacillus
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
KR100524872B1 (ko) 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US9012369B2 (en) 2004-07-06 2015-04-21 Pfizer Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
KR100852415B1 (ko) 2004-07-13 2008-08-18 재단법인서울대학교산학협력재단 인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
BRPI0610470A2 (pt) * 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
JP4959226B2 (ja) 2006-05-19 2012-06-20 独立行政法人産業技術総合研究所 スリーフィンガー様蛋白質ライブラリ
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
CN104825433A (zh) 2007-07-03 2015-08-12 达努塔·克鲁谢夫斯卡 α-酮戊二酸的新医药用途
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
CA2704229C (en) 2007-10-31 2019-05-07 Medimmune, Llc Protein scaffolds comprising seven beta strand domains and six loop regions
US20100322930A1 (en) 2007-12-27 2010-12-23 Frank Kolbinger Fibronectin-based binding molecules and their use
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
EP2352521B1 (en) * 2008-10-14 2020-09-16 Genentech, Inc. Immunoglobulin variants and uses thereof
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
WO2010128142A1 (en) 2009-05-07 2010-11-11 Novozymes Biopharma Dk A/S Method for purifying albumin
EP2464663A4 (en) 2009-08-13 2013-05-29 Massachusetts Inst Technology RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
WO2011051466A1 (en) * 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
ES2678144T3 (es) 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
WO2011130324A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
JP2014177354A (ja) 2011-07-05 2014-09-25 Asahi Glass Co Ltd 窓ガラス
HUE051439T2 (hu) * 2011-10-11 2021-03-01 Viela Bio Inc CD40L-re specifikus, TN3-eredetû állványok és alkalmazásuk
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
JP2017515828A (ja) 2014-05-19 2017-06-15 メディミューン リミテッド 関節リウマチのための治療
BR112017019401A2 (pt) 2015-03-12 2018-05-02 Medimmune, Llc método de purificação de proteínas de fusão de albumina
CA3114394A1 (en) 2018-09-26 2020-04-02 Viela Bio, Inc. Cd40l antagonist and uses thereof

Also Published As

Publication number Publication date
KR20220116585A (ko) 2022-08-23
US20180312572A1 (en) 2018-11-01
PT2771022T (pt) 2020-09-14
HK1201463A1 (en) 2015-09-04
US11555062B2 (en) 2023-01-17
AU2012323316A1 (en) 2014-03-20
MX2014004065A (es) 2014-08-22
LT2771022T (lt) 2020-12-10
MX2019009104A (es) 2019-09-10
US20220089688A1 (en) 2022-03-24
SG10201707813YA (en) 2017-11-29
ES2819075T3 (es) 2021-04-14
CN103874501B (zh) 2018-07-20
SI2771022T1 (sl) 2020-12-31
EP2771022A4 (en) 2015-08-05
JP6140712B2 (ja) 2017-05-31
DK2771022T3 (da) 2020-09-28
US20230242619A1 (en) 2023-08-03
HRP20201513T1 (hr) 2020-12-11
WO2013055745A2 (en) 2013-04-18
EP2771022B1 (en) 2020-07-01
RU2704992C2 (ru) 2019-11-01
JP2019205433A (ja) 2019-12-05
JP2015501147A (ja) 2015-01-15
JP6539300B2 (ja) 2019-07-03
KR20200085376A (ko) 2020-07-14
JP2022115916A (ja) 2022-08-09
SG11201400567QA (en) 2014-05-29
US11104720B2 (en) 2021-08-31
EP2771022A2 (en) 2014-09-03
RU2014117511A (ru) 2015-11-20
US10000553B2 (en) 2018-06-19
RS60828B1 (sr) 2020-10-30
JP2017195884A (ja) 2017-11-02
CN108948196A (zh) 2018-12-07
US20150098955A1 (en) 2015-04-09
AU2012323316B2 (en) 2017-08-10
KR102434073B1 (ko) 2022-08-18
HUE051439T2 (hu) 2021-03-01
CY1123690T1 (el) 2022-03-24
JP7068231B2 (ja) 2022-05-16
RU2019133467A (ru) 2020-07-06
CN116063509A (zh) 2023-05-05
KR20140077199A (ko) 2014-06-23
CN103874501A (zh) 2014-06-18
MX367013B (es) 2019-08-02
EP3753567A1 (en) 2020-12-23
CN108948196B (zh) 2022-09-23
WO2013055745A3 (en) 2013-08-01
CA2851667A1 (en) 2013-04-18
KR102132997B1 (ko) 2020-07-14

Similar Documents

Publication Publication Date Title
BR112014008804A2 (pt) suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
BR112014011594A2 (pt) anticorpos anti-il-36r
BR112014026703A2 (pt) inibidores de dna-pk
BR112014009866A2 (pt) formulações de anticorpos e métodos
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
BR112013029330A2 (pt) "uso de anticorpo imunoconjugado maitansinoide anti-cd19 na preparação de composição para tratamento de sintomas de doenças de célula-b, imunoconjugado maitansinoide anti-cd19 e artigo de fabricação"
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
BR112015000561A2 (pt) inibidores de irak e usos dos mesmos
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
BR112015009746A2 (pt) Agente que aumenta atividade de glicocerebrosidase em mamíferos
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
BR112014009962A2 (pt) anticorpos humanizados para inkt
WO2012138768A3 (en) Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIELA BIO, INC. (US)